17β-Estradiol inhibits cytokine induction of the human E-selectin promoter

Journal of Steroid Biochemistry and Molecular Biology

Volumn 80, Issue 3, 2002, Pages 291-297

  Tyree, Curtis M ^a,b   Zou, Aihua ^a   Allegretto, Elizabeth A ^a  

^a LIGAND PHARMACEUTICALS INC   (United States)

^b Neurogenetics Inc   (United States)

Author keywords

17 Estradiol; E selectin promoter; Estrogen receptor; NFK B

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ESTRADIOL; FULVESTRANT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LUCIFERASE; CYTOKINE; ESTROGEN RECEPTOR; PRIMER DNA;

ARTICLE; CONTROLLED STUDY; DNA BINDING; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; ENDOTHELIUM CELL; ENZYME ACTIVITY; EXPRESSION VECTOR; GENETIC TRANSFECTION; HEPATOMA CELL; HORMONE ACTION; HORMONE INHIBITION; HORMONE SUBSTITUTION; HUMAN; MUTATION; POINT MUTATION; PROTEIN EXPRESSION; UMBILICAL CORD; WILD TYPE; CELL LINE; GENE EXPRESSION REGULATION; GENETICS; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; PROMOTER REGION;

VECTORS;

BASE SEQUENCE; CELL LINE; CYTOKINES; DNA PRIMERS; E-SELECTIN; ESTRADIOL; GENE EXPRESSION REGULATION; HUMANS; LUCIFERASES; PROMOTER REGIONS (GENETICS); RECEPTORS, ESTROGEN;

EID: 0036010539     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(02)00022-5     Document Type: Article

References (47)

1. Estrogen and coronary heart disease in women
2. The effect of oestrogen on the female cardiovascular system
3. Sex, plasma lipoproteins and atherosclerosis: Prevailing assumptions and outstanding questions
4. Post-menopausal estrogen therapy and cardiovascular disease
5. The protective effects of estrogen on the cardiovascular system
6. Modulation of circulating cellular adhesion molecules in post-menopausal women with coronary artery disease
7. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic post-menopausal women
8. Elevated levels of sE-selectin in post-menopausal females are decreased by hormone replacement therapy to levels observed in pre-menopausal females
9. Effect of post-menopausal hormones on inflammation-sensitive proteins: The post-menopausal estrogen/progestin interventions (PEPI) study
10. Effects of oral, and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in post-menopausal women
11. Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy post-menopausal women
12. Effects of 17beta-estradiol on circulating adhesion molecules
13. Effects of hormone therapy on inflammatory cell adhesion molecules in post-menopausal healthy women
14. Association of circulating cellular adhesion molecules with menopausal status, and hormone replacement therapy, time-dependent change in transdermal, but not oral estrogen users
15. Modulation of endothelial cell expression of ICAM-1, E-selectin, and VCAM-1 by beta-estradiol, progesterone, and dexamethasone
16. Estradiol enhances leukocyte binding to tumor necrosis factor (TNF)-stimulated endothelial cells via an increase in TNF-induced adhesion molecules E-selectin, intercellular adhesion molecule type 1, vascular cell adhesion molecule type 1
17. Effects of 17beta-estradiol on cytokine-induced endothelial cell adhesion molecule expression
18. An NFKB-like factor is essential, but not sufficient for cytokine induction of endothelial leukocyte adhesion molecule-1 (ELAM-1) gene transcription
19. Structure and chromosomal location of the gene for endothelial leukocyte adhesion molecule-1
20. Activation of endothelial-leukocyte adhesion molecule-1 (ELAM-1) gene transcription
21. Cyclic AMP-independent ATF family members interact with NF-kappa B and function in the activation of the E-selectin promoter in response to cytokines
22. A striking similarity in the organization of the E-selectin and beta interferon gene promoters
23. cAMP and tumor necrosis factor competitively regulate transcriptional activation through and nuclear factor binding to the cAMP-responsive element/activating transcription factor element of the endothelial leukocyte adhesion molecule-1 (E-selectin) promoter
24. Cooperativity between two NF-kappa B complexes, mediated by high-mobility-group protein I (Y), is essential for cytokine-induced expression of the E-selectin promoter
25. Three NF-kappa B binding sites in the human E-selectin gene required for maximal tumor necrosis factor alpha-induced expression
26. Induction of the E-selectin promoter by interleukin-1 and tumour necrosis factor alpha, and inhibition by glucocorticoids
27. Glucocorticoids inhibit E-selectin expression by targeting NF-kappa B and not ATF/c-Jun
28. Estrogen and estrogen receptor antagonists stimulate transcription from the human retinoic acid receptor alpha-1 promoter via a novel sequence
29. Estrogen receptor beta activates the human retinoic acid receptor alpha-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen
30. Steroid receptor-mediated inhibition of rat prolactin gene expression does not require the receptor DNA-binding domain
31. Cloning and characterization of human ERβ isoforms
32. Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor
33. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta
34. Tamoxifen activation of the estrogen receptor/AP-1 pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens
35. Estradiol repression of tumor necrosis factor-alpha transcription requires estrogen receptor activation function-2 and is enhanced by co-activators
36. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta
37. Increased expression of estrogen receptor-beta mRNA in male blood vessels after vascular injury
38. Immunocytochemical demonstration of oestrogen receptor beta in blood vessels of the female rat
39. Differentiation between vasculoprotective and uterotrophic effects of ligands with different binding affinities to estrogen receptors alpha and beta
40. Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice
41. Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice
42. Involvement of CCAAT/enhancer-binding protein and nuclear factor-kappa B binding sites in interleukin-6 promoter inhibition by estrogens
43. Down-modulation of interleukin-6 gene expression by 17beta-estradiol in the absence of high affinity DNA binding by the estrogen receptor
44. 17beta-estradiol inhibits expression of human interleukin-6 promoter-reporter constructs by a receptor-dependent mechanism
45. Competition for p300 regulates transcription by estrogen receptors and nuclear factor-kappa B in human coronary smooth muscle cells
46. The role of CBP in estrogen receptor cross-talk with nuclear factor-kappa B in Hep G2 cells
47. Mutations in the estrogen receptor ligand binding domain discriminate between hormone-dependent transactivation and transrepression